InformAI Review: Everything You Need to Know

If you are reading an InformAI review right now, you are looking at one of the fastest-rising names in clinical AI at a moment when the FDA has authorized more than 1,300 AI-enabled medical devices, roughly three quarters of them in radiology (Source: U.S. Food and Drug Administration).

InformAI sits squarely in that regulatory current. The Houston company builds enterprise AI software for hospitals, and its flagship radiation therapy product cleared FDA 510(k) review in June 2026.

Search interest tells its own story. Exploding Topics data shows queries for the company up 2,900 percent over the past six months. That kind of spike usually means one of two things: hype, or a real clinical milestone. In InformAI’s case it is the second.

This review covers what the company actually builds, who each product serves, what is publicly known about pricing, and where the honest trade-offs sit.

Key Takeaways

• InformAI builds clinical AI software for radiation oncology, organ transplants, and CT diagnostics.
• Flagship product RadOncAI received FDA 510(k) clearance in June 2026.
• TransplantAI won a $2.2 million NIH Fast-Track award for donor-recipient matching.
• Pricing is enterprise-only and not publicly listed.
• Best fit: hospital systems and specialty clinics, not individual practitioners.

What Is InformAI?

InformAI is a health tech company founded in 2017 by Jim Havelka and based inside the Texas Medical Center in Houston, the largest medical complex in the world. The team is small, somewhere between 11 and 50 people, and the company has grown through a mix of venture backing and competitive government grants rather than a single large raise. Investors include DEFTA Partners, Delight Ventures, and Joyance Partners. Grant funders include the NIH, the NSF, and the Cancer Prevention and Research Institute of Texas.

That funding structure matters more than it might seem. Grant-funded clinical AI has to survive peer review and regulatory scrutiny before it ships, which tends to filter out vaporware. InformAI’s positioning inside JLABS @ TMC also gives it direct access to the clinicians and imaging data that AI healthcare companies typically struggle to reach.

The company describes its focus as high-acuity informatics. In plain terms, it builds decision-support software for the medical situations where the stakes are highest and the specialist’s time is scarcest.

The Product Lineup

InformAI runs three products at different stages of maturity. Each one targets a specific clinical bottleneck.

RadOncAI

RadOncAI is the flagship, and the reason the company is trending. It is an AI dose-planning tool for radiation oncology. When a head and neck cancer patient needs radiation therapy, a clinical team normally spends hours building a plan that targets the tumor while sparing healthy tissue. RadOncAI generates an optimized first-pass plan in about five minutes.

The June 2026 FDA 510(k) clearance covers this software as a clinician co-pilot for head and neck cancer dose planning. That word co-pilot is doing real work. The system does not replace the radiation oncologist. It hands them a starting plan built on the expertise of top-tier institutions, which is a meaningful equity play for community hospitals that cannot recruit subspecialist planners.

TransplantAI

TransplantAI is a donor-recipient informatics platform. Organ allocation is one of medicine’s hardest optimization problems: organs get discarded, matches happen under time pressure, and urgency scoring is blunt. TransplantAI was trained on roughly one million donor transplant records and produces granular match recommendations at the point of care, including expected 90-day mortality for candidate recipients.

The product recently received a $2.2 million NIH Fast-Track Phase 2 award to fund development and commercialization. It is not yet a cleared medical device, so treat it as a strong pipeline product rather than something you can deploy tomorrow.

SinusAI

SinusAI applies image classification to sinus CT scans, helping ENT practices and radiologists read studies faster. It is the earliest-stage product of the three and the least documented publicly. If sinus diagnostics is your use case, expect to talk to the company directly about availability.

Who InformAI Is For

This is enterprise clinical software. The buyer is a hospital system, a radiation oncology department, a transplant center, or a large specialty group, working through IT, compliance, and clinical leadership. The tools plug into existing diagnosis and treatment workflows rather than replacing them.

If you run a small practice or you are an individual clinician looking for a subscription tool, InformAI is not built for you. There is no self-serve tier and no consumer product. The company sells into institutions that can support a regulated software deployment, and that is a deliberate choice given the FDA pathway its products follow.

Pricing

InformAI pricing is not publicly listed. That is normal for software-as-a-medical-device sold to health systems, where contracts depend on facility size, integration scope, and support terms. Budget expectations should follow enterprise clinical software norms, and any real number will come from a direct sales conversation.

Pros and Cons

Pros

• FDA 510(k) clearance for RadOncAI, a bar most clinical AI startups never reach
• Deep clinical grounding from its Texas Medical Center location and physician advisors
• Grant validation from NIH, NSF, and CPRIT, which requires independent scientific review
• Clear equity benefit: community hospitals get plans in line with tier-one institutions
• Focused product scope instead of a sprawling do-everything platform

Cons

• No public pricing, so evaluation requires a sales process
• TransplantAI and SinusAI are still pipeline products, not cleared devices
• Small team, which can mean slower support and integration timelines than large vendors
• RadOncAI’s cleared indication is currently specific to head and neck cancer
• Limited independent user reviews available, since deployments are institutional

How It Compares to Alternatives

InformAI competes in radiation oncology planning against much larger players. RaySearch Laboratories ships machine learning planning inside RayStation, Varian’s Ethos platform handles adaptive therapy, and startups like MVision AI and Limbus AI focus on auto-contouring, one step upstream of dose planning. The big vendors win on breadth and installed base. InformAI’s edge is a purpose-built dose prediction model and a lighter footprint for hospitals that do not want to replace their whole treatment planning stack.

In transplant informatics, there is no directly comparable cleared product, which is exactly why the NIH is funding the work. The practical alternative today is the existing allocation infrastructure plus institutional judgment.

For hospital operations teams weighing where AI budget goes first, it is worth remembering that the fastest returns industry-wide still come from workflow and documentation automation. InformAI plays a different game: clinical decision support in high-stakes specialties. The two are complements, not substitutes.

Conclusion

InformAI has done the hard, unglamorous things that separate durable clinical AI companies from demos. It embedded inside the world’s largest medical center, funded development through peer-reviewed grants, and pushed its flagship product through FDA clearance. If you are evaluating AI for radiation oncology, RadOncAI belongs on your shortlist, especially if your facility treats head and neck cancer and lacks subspecialist planning capacity.

Go in with clear eyes about the rest. TransplantAI is promising but pre-clearance, SinusAI is early, and pricing requires a conversation. Ask the company about integration timelines, indication expansion plans, and validation data for your patient population. Those answers will tell you whether the 2,900 percent search spike reflects your reality or just the market’s excitement.

Read Next

Keep exploring how AI is reshaping clinical care:

• Reinventing Patient Care: How AI and Remote Monitoring Are Changing Medicine
• How Healthcare AI Is Driving the Next Wave of Digital Transformation
• What is the Difference Between AI and Machine Learning in Healthcare?

Frequently Asked Questions